



(51) International Patent Classification:

A61K 47/68 (2017.01) C07K 16/28 (2006.01)  
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2021/061660

(22) International Filing Date:

02 December 2021 (02.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,044 03 December 2020 (03.12.2020) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive  
S.E., Bothell, Washington 98021 (US).

(72) Inventors: HEISER, Ryan A.; c/o Seagen Inc., 21823 30th  
Drive, S.E., Bothell, Washington 98021 (US). GROGAN,  
Bryan M.; c/o Seagen Inc., 21823 30th Drive, S.E., Bothell,  
Washington 98021 (US).

(74) Agent: LEKUTIS, Christine et al.; Morrison & Foerster  
LLP, 425 Market Street, San Francisco, California 94105  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,


GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES

FIG. 1A



(57) Abstract: Provided herein are anti-CD30 antibody-drug conjugates and methods of using the same to modulate the immune response in a subject.

[Continued on next page]

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*